The acquired company, CymaBay Therapeutics, is a Newark, Calif.-based drug manufacturer focused on primary biliary cholangitis. PBC is a rare chronic liver disease that mainly affects women, with a prevalence of 130,000 people in the U.S.
Gilead’s purchase adds CymaBay’s lead drug candidate, seladelpar, to its portfolio, according to a Gilead news release. The FDA is reviewing seladelpar’s tentative approval, and its decision is expected by Aug. 14.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
